Healthcare Edge hosted a fireside chat from the floor of the New York Stock Exchange with Marc Hedrick, M.D., President and CEO of Plus Therapeutics, Inc. (Nasdaq: PSTV). Dr. Hedrick spoke to Healthcare Edge Editor-in-Chief John Jannarone about its novel...

Tech Edge hosted a fireside chat from the floor of the New York Stock Exchange with Vlad Shmunis, Founder and Executive Chairman of RingCentral (NYSE: RNG), and Tarek Robbiati, its new CEO. Mr. Shmunis and Mr. Robbiati spoke to  Tech...

In an interview with Cheddar TV’s Kristen Scholer, Tech Edge Editor-in-Chief John Jannarone provided tips on navigating IPOs as a retail investor, with chip maker Arm Holdings plc making its debut on the NASDAQ in the biggest IPO of the year. Institutional investors...

By Daniella Parra ProSomnus, Inc. (NASDAQ: OSA) is set to feature its precision sleep apnea devices in upcoming medical conferences, showcasing new data on the efficacy, safety and effectiveness of ProSomnus devices, it said. One study compared precision oral appliance...

By Tech Edge Editorial Qualtrics’ “Complaints and Grievances” solution for the healthcare industry will help improve the patient experience, which can be deeply personal, frightening and fraught with layers of process and paperwork, according to The Futurum Group. The solution...

By Karen E. Roman The Federal Communications Commission (FCC) is assessing the potential threat of Chinese cellular devices to track and infiltrate U.S. intelligence through connected devices on the Internet of Things (IoT), according to a recent article from The...

By Daniella Parra Sparrow Pharmaceuticals expanded its Phase 2 clinical trial for SPI-62 in combination with prednisolone to treat polymyalgia rheumatica (PMR), the company said. The trial is exploring the potential benefits of SPI-62 in reducing the side effects of...

By Tech Edge Editorial MongoDB (Nasdaq: MDB), a data platform player company, reported total revenue of $423.8 million in its second quarter results, a 40% increase year-over-year. The company saw a gross profit of $318.5 million, 75% gross margin compared...

By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company specializing in advanced radiotherapeutics for brain cancer, said it will present data from its ReSPECT-LM clinical trial at the CPRIT Innovations in Cancer Prevention and Research Conference VI....

By Daniella Parra Plus Therapeutics, Inc. (Nasdaq: PSTV) has expanded its partnership with Biocept with an exclusive option to license a diagnostic platform for central nervous system cancer patients undergoing radiotherapy, the company said. CNSide is a proprietary assay that...